Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Daniela Hoehn"'
Autor:
Abdullah Mahmood Ali, Yumin Huang, Ronald Feitosa Pinheiro, Fumin Xue, Jingping Hu, Nicholas Iverson, Daniela Hoehn, Diego Coutinho, Jehanzeb Kayani, Brian Chernak, Joseph Lane, Christopher Hillyer, Naomi Galili, Joseph Jurcic, Narla Mohandas, Xiuli An, Azra Raza
Publikováno v:
Blood Advances, Vol 2, Iss 12, Pp 1393-1402 (2018)
Abstract: Anemia is the defining feature in most patients with myelodysplastic syndromes (MDS), yet defects in erythropoiesis have not been well characterized. We examined freshly obtained bone marrow (BM) samples for stage-specific abnormalities dur
Externí odkaz:
https://doaj.org/article/53545c28418145669201fd7942148022
Autor:
Kamraan Z Gill, Fabio Iwamoto, Ashleigh Allen, Daniela Hoehn, Vundavalli V Murty, Bachir Alobeid, Govind Bhagat
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114398 (2014)
Primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) is a rare, aggressive subtype of DLBCL, the biology of which is poorly understood. Recent studies have suggested a prognostic role of MYC protein expression in systemic D
Externí odkaz:
https://doaj.org/article/59a5e5510ccc4cc2be585ec4b8c3399d
Autor:
Habte, Yimer, Jason, Melear, Edward, Faber, William I, Bensinger, John M, Burke, Mohit, Narang, Don, Stevens, Kathleen S, Gray, Yana, Lutska, Padma, Bobba, Keqin, Qi, Daniela, Hoehn, Ming, Qi, Thomas S, Lin, Robert M, Rifkin
Publikováno v:
Leukemia & Lymphoma. 63:2383-2392
In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). We report the final analysis of
Autor:
Owen A. O'Connor, Simon Jones, Yuan Zhang, Serge Cremers, Hongfeng Jiang, Jennifer Heinen, Dejan Radeski, Xavier Jirau-Serrano, Luigi Scotto, Govind Bhagat, Daniela Hoehn, Kelly Zullo, Maximilian Lombardo, Paul Johannet, Jennifer E. Amengual
Purpose: Pan-class histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. HDAC6 is a class IIb deacetylase that facilitates misfolded pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65c138e0e4b7e1256e44af768ef5d82
https://doi.org/10.1158/1078-0432.c.6524379.v1
https://doi.org/10.1158/1078-0432.c.6524379.v1
Autor:
Owen A. O'Connor, Simon Jones, Yuan Zhang, Serge Cremers, Hongfeng Jiang, Jennifer Heinen, Dejan Radeski, Xavier Jirau-Serrano, Luigi Scotto, Govind Bhagat, Daniela Hoehn, Kelly Zullo, Maximilian Lombardo, Paul Johannet, Jennifer E. Amengual
Peripheral blood mononuclear cells (PBMCs) were separated from whole blood by Ficoll-Paque layering. (A) Concentration : effect relationship was determined for ACY-1215 at 24 and 48 hours in PBMCs. No cytotoxicity was observed after 24 and 48 hours o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1ddbfe259b925651164d93eff2ddec
https://doi.org/10.1158/1078-0432.22460022
https://doi.org/10.1158/1078-0432.22460022
Autor:
Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat
Publikováno v:
Blood. 140:850-851
Autor:
Peter M. Voorhees, Padma Bobba, Daniela Hoehn, Huiling Pei, Yana Lutska, Jon Ukropec, Thomas S. Lin, Ming Qi, Nitya Nathwani, Cesar Rodriguez, Brandi Reeves, Luciano J. Costa, Paul G. Richardson
Publikováno v:
Blood Adv
The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in phase followed by a randomized phase. The ongoing randomized phase has met
Autor:
Larry D. Anderson, Jacob P. Laubach, Tanya M. Wildes, Andrew J. Cowan, Nina Shah, Douglas W. Sborov, Andrzej Jakubowiak, Yana Lutska, Cesar Rodriguez, Jonathan L. Kaufman, Nitya Nathwani, Peter M. Voorhees, Sarah A. Holstein, Daniela Hoehn, Luciano J. Costa, Carla de Boer, Yvonne A. Efebera, Thomas S. Lin, Paul G. Richardson, Brandi Reeves, Huiling Pei, Jon Ukropec, Kenneth H. Shain, Ajai Chari, Rebecca Silbermann, Caitlin Costello, Jessica Vermeulen, Robert Z. Orlowski, Sean Murphy
Publikováno v:
Blood. 136(8)
Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The addition of daratumumab (D) to
Autor:
Michel R. Nasr, Neerja Vajpayee, Alan D. Hutson, Michael R. Lewis, Claudiu V. Cotta, James E. Coad, Gregory E. Wilding, Kieran Sultan, Sinisa Ivelja, John T Grantham, Richard Cheney, Gratian Salaru, Mihai Merzianu, Guilherme Brandao, Prabhjot Kaur, Valentin G. Robu, Shanxiang Zhang, John Lazarchick, Attilio Orazi, Sindhu Cherian, LoAnn Peterson, Ling Zhang, Robert W. McKenna, Jerome B. Myers, Jeffrey A. Vos, Ridas Juskevicius, Elizabeth L. Courville, Adrienne Groman, Rodney R. Miles, Elisa Brega, Robert E. Hutchison, David D. Grier, Vishnu Reddy, Daniela Hoehn, Guang Fan, Russell K. Brynes, Manjula Balasubramanian, Horatiu Olteanu, Ramila Amre, Julie Teruya-Feldstein, Kedar V. Inamdar, Hina Naushad Qureishi, David R. Czuchlewski, Le Aye
Publikováno v:
American Journal of Clinical Pathology. 150:393-405
Objectives To assess bone marrow (BM) sampling in academic medical centers. Methods Data from 6,374 BM samples obtained in 32 centers in 2001 and 2011, including core length (CL), were analyzed. Results BM included a biopsy (BMB; 93%) specimen, aspir
Autor:
Huiling Pei, Padma Bobba, Paul G. Richardson, Brandi Reeves, Peter M. Voorhees, Daniela Hoehn, Cesar Rodriguez, Luciano J. Costa, Nitya Nathwani, Ming Qi, Thomas S. Lin, Jon Ukropec, Yana Lutska
Publikováno v:
Blood. 136:48-49
Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved in combination with bortezomib, thalidomide and dexamethasone for transplant-eligible NDMM; however, RVd is the standard of care in the US for transplant-eligible NDMM.